Philippe Mauberna

Philippe Mauberna is Chief Financial Officer of Genespire.

Prior to that, Philippe served as Chief Financial Officer and Executive Board member of Nanobiotix SA since 2013, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, where he actively led the company development and its financial footprint with a successful IPO on the Nasdaq in Dec 2020.

Prior to Nanobiotix, Philippe served as General Manager of MitryChem, a CMO, as Principal, Life Sciences at Capgemini Consulting and in senior financial and operational roles at Astellas Pharma France & EMEA headquarters from 2002 to 2008. As expert in management and development of financial and operational projects for the pharmaceutical industry, Philippe has been involved in several international prjects (UK, Saudi Arabia, South Africa and Indonesia). He has also been heavily involved in financial projects for start-up launches and innovative small and medium-size enterprise development. As a consultant, he has provided strategic change management support for European pharmaceutical companies during their development phases.

Mr. Mauberna received his master’s degree in finance, management, administration and economy from University Paris 2 Assas and his specialized master’s in finance, marketing and law from ISG (Institut Supérieur de Gestion), extended by management training from INSEAD, Paris.